Otros idiomas AstraZeneca PLC

Acciones

AZN

GB0009895292

Farmacéuticos

Tiempo real estimado Cboe Europe Otros sitios de cotización 10:53:34 13/12/2024			Varia. Cinco días.	Varia. 1 de enero.
10.501,00 ^GBX	-0,63 %		-1,52 %	-1,02 %

12/12	Los gigantes bursátiles presionan a los proveedores con plazos de pago extremos - Di	FW
11/12	Merck y AstraZeneca desvelan los resultados a largo plazo de Lynparza	AN

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

AstraZeneca and Merck - LYNPARZA Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial	12/12
Astrazeneca - Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial	12/12
AstraZeneca : Lynparza prometteur en cancer du sein	12/12
Merck and AstraZeneca unveil long-term Lynparza results	11/12
AstraZeneca, Merck's Lynparza Shows Prolonged Survival Benefit in Early Breast Cancer Patients	11/12
LYNPARZA® Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial	11/12
LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial	11/12
Medera?S Novoheart Releases Latest Cardiac Screening Innovation Ctscreen V1.5 to Advance High-Throughput, Automated Human-Based Drug Testing	10/12
Global markets live: BlackRock, Apple, Comcast, Boeing, Palantir...	09/12
AstraZeneca - IMFINZI granted Priority Review in the US for patients with muscle-invasive bladder cancer	09/12
Astrazeneca - Fixed-duration Calquence plus venetoclax demonstrated superior progression-free survival vs. standard of care in previously untreated chronic lymphocytic leukaemia	09/12
Astrazeneca Reports Positive Phase 3 Calquence Data for Chronic Lymphocytic Leukemia	09/12
Astrazeneca, Daiichi Sankyo's Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in US	09/12
ASTRAZENECA : Baking in some caution due to the ongoing challenges in China	09/12
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer	09/12
AstraZeneca, Daiichi Sankyo hail US breakthrough therapy designation	09/12
FTSE 100 : London rises, trailing global markets	09/12
AstraZeneca : obtient une désignation 'Breakthrough Therapy'	09/12
AstraZeneca : résultats prometteurs dans la leucémie	09/12
Boohoo gets ISS backing amid Frasers Group spat	09/12
En Direct des Marchés : Vivendi à la découpe, Crédit Agricole contre-attaque et mariage dans la pub	09/12
AstraZeneca, Daiichi Sankyo's Lung Cancer Treatment Receives Breakthrough Designation from US FDA	09/12
AstraZeneca : Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR mutated non small cell lung cancer	09/12
Datopotamab Deruxtecan Grants Breakthrough Therapy Designation in U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer	09/12
Ça baisse plus	09/12

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Titulares

ASTRAZENECA : Mostrando cierta cautela debido a los continuos desafíos en China

09 de diciembre 2024 a las 13:38

Pascal Soriot, CEO de AstraZeneca : Un nuevo tratamiento contra el cáncer de pulmón mejora la supervivencia en dos meses

10 de septiembre 2024 a las 13:48